Lenalidomide Accord (Lenalidomide)

Lenalidomide is an immunomodulatory agent indicated for specific hematologic malignancies and related disorders.

• Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes (del(5q) cytogenetic abnormality): reduces transfusion dependence and may improve blood counts.
• Mantle Cell Lymphoma: used in combination regimens to achieve disease control in adult patients.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This modulation alters cytokine production, enhances T‑cell and NK‑cell mediated immunity, and inhibits angiogenesis, resulting in anti‑proliferative and pro‑apoptotic effects on malignant cells.

Lenalidomide may cause a range of adverse reactions, from mild to severe. Monitoring and supportive care are essential during therapy.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Neutropenia: lowered neutrophil count increasing infection risk.
• Thrombocytopenia: reduced platelet count leading to easy bruising.
• Diarrhea: loose stools that may require hydration.
• Nausea: upset stomach often managed with anti‑emetics.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: profound infection susceptibility.
• Severe thrombocytopenia: risk of serious bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Hepatic failure: significant liver enzyme elevation or dysfunction.

Before initiating Lenalidomide, clinicians should assess several safety parameters and educate patients on risk mitigation.

• Blood Count Monitoring: perform complete blood counts regularly to detect cytopenias.
• Thrombotic Risk Assessment: evaluate history of clotting disorders and consider prophylactic anticoagulation.
• Renal Function Evaluation: adjust therapy if creatinine clearance is reduced.
• Pregnancy Prevention: enforce strict contraception for both male and female patients of reproductive potential.
• Concomitant Medication Review: avoid drugs that may exacerbate hematologic toxicity.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lenalidomide interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.
• Live vaccines: potential for uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal bleeding.
• Digoxin: possible alteration of serum concentrations requiring monitoring.